COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03697590
Recruitment Status : Completed
First Posted : October 5, 2018
Last Update Posted : October 9, 2018
Information provided by (Responsible Party):
Ida M. Heerfordt, Bispebjerg Hospital

Brief Summary:
Guidelines for photodynamic therapy (PDT) of actinic keratosis recommend pretreatment with curettage. The impact of curettage on the treatment effect is, however, not known. The present study aimed to evaluate whether daylight-PDT without curettage would reduce treatment effect compared to daylight-PDT with curettage.

Condition or disease Intervention/treatment Phase
Keratosis, Actinic Drug: No curettage Drug: Curettage Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage
Actual Study Start Date : June 1, 2017
Actual Primary Completion Date : December 20, 2017
Actual Study Completion Date : December 20, 2017

Arm Intervention/treatment
Experimental: PDT with no curettage Drug: No curettage
Standard PDT without curettage

Active Comparator: Standard PDT Drug: Curettage
Standard PDT

Primary Outcome Measures :
  1. Complete lesion response rate [ Time Frame: Treatment efficacy was evaluated 3 months after PDT ]
    Complete lesion response rate, was defined as the number of completely responding lesions divided by the total number of treated lesion in each field. Complete lesion response was defined as complete disappearance of the lesion both by palpation and visually.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Multiple actinic keratosis on the forehead or scalp

Exclusion Criteria:

  • Known allergy to methyl aminolevulinate
  • Porphyria
  • Pregnancy
  • Lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03697590

Layout table for location information
Bispebjerg Hospital
Copenhagen NV, DK, Denmark, 2400
Sponsors and Collaborators
Bispebjerg Hospital
Layout table for additonal information
Responsible Party: Ida M. Heerfordt, Principal investigator, MD, PhD, Bispebjerg Hospital Identifier: NCT03697590    
Other Study ID Numbers: PDT with and without curettage
First Posted: October 5, 2018    Key Record Dates
Last Update Posted: October 9, 2018
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Keratosis, Actinic
Skin Diseases
Precancerous Conditions